Total: 1699

    The advisory committee on immunization practices’ interim recommendation for use of Pfizer-Biontech Covid-19 vaccine in children aged 5–11 years: United States, november 2021

    MMWR recomm. rep; 70 (45), 2022
    The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle–formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. On August 23, 2021, the Food and Drug Administration (FDA) approved a Biologics License Applicati...

    WHO recommendations on induction of labour, at or beyond term

    The primary audience for these recommendations includes health professionals who are responsible for developing national and local health-care guidelines and protocols and health workers involved in the provision of care to women and their newborns during pregnancy, labour and childbirth; this includes m...

    WHO recommendations on mechanical methods for induction of labour

    The primary audience for these recommendations includes health professionals who are responsible for developing national and local health-care guidelines and protocols and health workers involved in the provision of care to women and their newborns during pregnancy, labour and childbirth; this includes m...

    WHO recommendation on tocolytic therapy for improving preterm birth outcomes

    In 2021, the Executive Guideline Steering Group (GSG) for the World Health Organization (WHO) maternal and perinatal health recommendations prioritized updating the then current recommendations on the use of tocolysis as published in the WHO recommendations on interventions to improve preterm birth outco...

    WHO recommendations on antenatal corticosteroids for improving preterm birth outcomes

    In 2021, the Executive Guideline Steering Group (GSG) for the World Health Organization (WHO) maternal and perinatal health recommendations prioritized updating the then current recommendations on the use of antenatal corticosteroids as published in the WHO recommendations on interventions to improve pre...

    Therapeutics and COVID-19: living guideline - 16 September 2022

    The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an online platform, an...

    Clinical management of COVID-19: living guideline - 15 September 2022

    The WHO COVID-19 Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with COVID-19. Providing guidance that is comprehensive and holistic for the optimal care of COVID-19 patients throughout their entire illness is impor...

    Guia practica clinica para el manejo de parto pretermino

    El parto pretérmino en la región centroamericana tiene variaciones en cada país, así como la mortalidad perinatal neonatal y materna que se deriva de la condición. La atención adecuada sigue siendo una barrera en las zonas con más limitaciones en los servicios y el personal sanitario disponible. E...

    Novavax COVID-19 vaccine local reactions, systemic reactions, adverse events, and serious adverse events

    Local reactions were reported by the majority of vaccine recipients and at higher rates than placebo recipients (75.3% vs 20.6% after dose 2). Pain/tenderness at the injection site was the most common and most severe local reaction among vaccine recipients and reported more frequently after dose 2 than a...

    Guidelines on long-acting injectable cabotegravir for HIV prevention

    In this guideline, WHO recommends that long-acting injectable cabotegravir (CAB-LA) may be offered as an additional HIV prevention option for people at substantial risk of HIV infection. CAB-LA is an injectable form of pre-exposure prophylaxis (PrEP) that has been shown to be highly effective at reducing...